ID   ACY2_HUMAN              Reviewed;         313 AA.
AC   P45381;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   28-JUN-2023, entry version 198.
DE   RecName: Full=Aspartoacylase;
DE            EC=3.5.1.15 {ECO:0000269|PubMed:24036223, ECO:0000269|PubMed:28101991};
DE   AltName: Full=Aminoacylase-2;
DE            Short=ACY-2;
GN   Name=ASPA; Synonyms=ACY2, ASP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT CAND ALA-285.
RC   TISSUE=Kidney;
RX   PubMed=8252036; DOI=10.1038/ng1093-118;
RA   Kaul R., Gao G.P., Balamurugan K., Matalon R.;
RT   "Cloning of the human aspartoacylase cDNA and a common missense mutation in
RT   Canavan disease.";
RL   Nat. Genet. 5:118-123(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   CHARACTERIZATION, CHARACTERIZATION OF VARIANT CAND ALA-285, AND MUTAGENESIS
RP   OF GLU-285.
RC   TISSUE=Brain;
RX   PubMed=12706335; DOI=10.1016/s0003-9861(03)00055-9;
RA   Moore R.A., Le Coq J., Faehnle C.R., Viola R.E.;
RT   "Purification and preliminary characterization of brain aspartoacylase.";
RL   Arch. Biochem. Biophys. 413:1-8(2003).
RN   [4]
RP   CATALYTIC ACTIVITY, ZINC-BINDING SITES, ACTIVE SITE, AND MUTAGENESIS OF
RP   GLU-178.
RX   PubMed=17027983; DOI=10.1016/j.febslet.2006.09.056;
RA   Herga S., Berrin J.G., Perrier J., Puigserver A., Giardina T.;
RT   "Identification of the zinc binding ligands and the catalytic residue in
RT   human aspartoacylase, an enzyme involved in Canavan disease.";
RL   FEBS Lett. 580:5899-5904(2006).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) IN COMPLEXES WITH ZINC IONS;
RP   PHOSPHATE AND N-PHOSPHONOMETHYL-L-ASPARTATE, COFACTOR, SUBUNIT, AND
RP   MUTAGENESIS OF ARG-71; TYR-164; ARG-168; GLU-178 AND TYR-288.
RX   PubMed=18293939; DOI=10.1021/bi702400x;
RA   Le Coq J., Pavlovsky A., Malik R., Sanishvili R., Xu C., Viola R.E.;
RT   "Examination of the mechanism of human brain aspartoacylase through the
RT   binding of an intermediate analogue.";
RL   Biochemistry 47:3484-3492(2008).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEX WITH ZINC IONS, SUBUNIT,
RP   AND COFACTOR.
RX   PubMed=17194761; DOI=10.1073/pnas.0607817104;
RA   Bitto E., Bingman C.A., Wesenberg G.E., McCoy J.G., Phillips G.N. Jr.;
RT   "Structure of aspartoacylase, the brain enzyme impaired in Canavan
RT   disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:456-461(2007).
RN   [7]
RP   VARIANTS CAND ALA-285 AND GLU-305.
RX   PubMed=8023850;
RA   Kaul R., Gao G.P., Aloya M., Balamurugan K., Petrosky A., Michals K.,
RA   Matalon R.;
RT   "Canavan disease: mutations among Jewish and non-Jewish patients.";
RL   Am. J. Hum. Genet. 55:34-41(1994).
RN   [8]
RP   VARIANTS CAND 176-GLY-ILE-177 DEL; ARG-274; SER-295 AND GLU-305.
RX   PubMed=7668285;
RA   Shaag A., Anikster Y., Christensen E., Glustein J.Z., Fois A.,
RA   Michelakakis H., Nigro F., Pronicka E., Ribes A., Zabot M.-T.,
RA   Elpeleg O.N.;
RT   "The molecular basis of canavan (aspartoacylase deficiency) disease in
RT   European non-Jewish patients.";
RL   Am. J. Hum. Genet. 57:572-580(1995).
RN   [9]
RP   VARIANT CAND ARG-152.
RX   PubMed=7599639; DOI=10.1002/humu.1380050313;
RA   Kaul R., Gao G.P., Michals K., Whelan D.T., Levin S., Matalon R.;
RT   "Novel (Cys152 > Arg) missense mutation in an Arab patient with Canavan
RT   disease.";
RL   Hum. Mutat. 5:269-271(1995).
RN   [10]
RP   VARIANTS CAND THR-16; ARG-27; GLU-114; GLU-123; TYR-152; CYS-168; ALA-285
RP   AND GLU-305, VARIANT GLY-310, AND CHARACTERIZATION OF VARIANTS CAND THR-16;
RP   ARG-27; GLU-114; GLU-123; TYR-152 AND CYS-168.
RX   PubMed=8659549;
RA   Kaul R., Gao G.P., Matalon R., Aloya M., Su Q., Jin M., Johnson A.B.,
RA   Schutgens R.B.H., Clarke J.T.R.;
RT   "Identification and expression of eight novel mutations among non-Jewish
RT   patients with Canavan disease.";
RL   Am. J. Hum. Genet. 59:95-102(1996).
RN   [11]
RP   VARIANT CAND THR-143.
RX   PubMed=9452117; DOI=10.1002/humu.1380110196;
RA   Kobayashi K., Tsujino S., Ezoe T., Hamaguchi H., Nihei K., Sakuragawa N.;
RT   "Missense mutation (I143T) in a Japanese patient with Canavan disease.";
RL   Hum. Mutat. Suppl. 1:S308-S309(1998).
RN   [12]
RP   VARIANT CAND CYS-231.
RX   PubMed=10564886;
RX   DOI=10.1002/(sici)1096-8628(19991126)87:3<273::aid-ajmg17>3.0.co;2-o;
RA   Rady P.L., Vargas T., Tyring S.K., Matalon R., Langenbeck U.;
RT   "Novel missense mutation (Y231C) in a Turkish patient with Canavan
RT   disease.";
RL   Am. J. Med. Genet. 87:273-275(1999).
RN   [13]
RP   VARIANTS CAND THR-16; ARG-27; HIS-183; PHE-186; ARG-195; ARG-274; SER-280;
RP   LEU-280; THR-287; SER-295 AND GLU-305.
RX   PubMed=10407784; DOI=10.1023/a:1005512524957;
RA   Elpeleg O.N., Shaag A.;
RT   "The spectrum of mutations of the aspartoacylase gene in Canavan disease in
RT   non-Jewish patients.";
RL   J. Inherit. Metab. Dis. 22:531-534(1999).
RN   [14]
RP   VARIANTS CAND PRO-21; THR-57; HIS-168 AND THR-181.
RX   PubMed=10909858; DOI=10.1038/sj.ejhg.5200477;
RA   Sistermans E.A., de Coo R.F., van Beerendonk H.M., Poll-The B.T.,
RA   Kleijer W.J., van Oost B.A.;
RT   "Mutation detection in the aspartoacylase gene in 17 patients with Canavan
RT   disease: four new mutations in the non-Jewish population.";
RL   Eur. J. Hum. Genet. 8:557-560(2000).
RN   [15]
RP   VARIANTS CAND GLY-24; ALA-68; TRP-152; ARG-244 AND VAL-249.
RX   PubMed=12638939; DOI=10.1023/a:1022091223498;
RA   Zeng B.J., Wang Z.H., Ribeiro L.A., Leone P., De Gasperi R., Kim S.J.,
RA   Raghavan S., Ong E., Pastores G.M., Kolodny E.H.;
RT   "Identification and characterization of novel mutations of the
RT   aspartoacylase gene in non-Jewish patients with Canavan disease.";
RL   J. Inherit. Metab. Dis. 25:557-570(2002).
RN   [16]
RP   VARIANTS CAND TYR-114 AND VAL-249.
RX   PubMed=12205125; DOI=10.1136/jmg.39.9.e55;
RA   Olsen T.R., Tranebjaerg L., Kvittingen E.A., Hagenfeldt L., Moller C.,
RA   Nilssen O.;
RT   "Two novel aspartoacylase gene (ASPA) missense mutations specific to
RT   Norwegian and Swedish patients with Canavan disease.";
RL   J. Med. Genet. 39:E55-E55(2002).
RN   [17]
RP   VARIANT CAND THR-177, AND CATALYTIC ACTIVITY.
RX   PubMed=24036223; DOI=10.1016/j.clinbiochem.2013.09.004;
RA   Di Pietro V., Cavallari U., Amorini A.M., Lazzarino G., Longo S.,
RA   Poggiani C., Cavalli P., Tavazzi B.;
RT   "New T530C mutation in the aspartoacylase gene caused Canavan disease with
RT   no correlation between severity and N-acetylaspartate excretion.";
RL   Clin. Biochem. 46:1902-1904(2013).
RN   [18]
RP   VARIANTS CAND LYS-24; PRO-30; VAL-57; THR-63; ARG-69; VAL-101; LYS-129;
RP   THR-170; VAL-180; HIS-204; ARG-248 AND ASP-286, CHARACTERIZATION OF
RP   VARIANTS CAND LYS-24; PRO-30; VAL-57; THR-63; ARG-69; VAL-101; LYS-129;
RP   THR-170; VAL-180; HIS-204; ARG-248; ALA-285 AND ASP-286, CATALYTIC
RP   ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=28101991; DOI=10.1002/humu.23181;
RA   Mendes M.I., Smith D.E., Pop A., Lennertz P., Fernandez Ojeda M.R.,
RA   Kanhai W.A., van Dooren S.J., Anikster Y., Baric I., Boelen C.,
RA   Campistol J., de Boer L., Kariminejad A., Kayserili H., Roubertie A.,
RA   Verbruggen K.T., Vianey-Saban C., Williams M., Salomons G.S.;
RT   "Clinically distinct phenotypes of Canavan disease correlate with residual
RT   aspartoacylase enzyme activity.";
RL   Hum. Mutat. 38:524-531(2017).
CC   -!- FUNCTION: Catalyzes the deacetylation of N-acetylaspartic acid (NAA) to
CC       produce acetate and L-aspartate. NAA occurs in high concentration in
CC       brain and its hydrolysis NAA plays a significant part in the
CC       maintenance of intact white matter. In other tissues it acts as a
CC       scavenger of NAA from body fluids.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-acyl-L-aspartate = a carboxylate + L-aspartate;
CC         Xref=Rhea:RHEA:10872, ChEBI:CHEBI:15377, ChEBI:CHEBI:29067,
CC         ChEBI:CHEBI:29991, ChEBI:CHEBI:58497; EC=3.5.1.15;
CC         Evidence={ECO:0000269|PubMed:17027983, ECO:0000269|PubMed:24036223,
CC         ECO:0000269|PubMed:28101991};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:17194761, ECO:0000269|PubMed:18293939};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:17194761,
CC       ECO:0000269|PubMed:18293939};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         Vmax=1.2 nmol/h/mg enzyme {ECO:0000269|PubMed:28101991};
CC   -!- SUBUNIT: Homodimer. {ECO:0000305|PubMed:17194761,
CC       ECO:0000305|PubMed:18293939}.
CC   -!- INTERACTION:
CC       P45381; Q96HD9: ACY3; NbExp=15; IntAct=EBI-750475, EBI-3916242;
CC       P45381; P45381: ASPA; NbExp=2; IntAct=EBI-750475, EBI-750475;
CC       P45381; Q9UNS2: COPS3; NbExp=3; IntAct=EBI-750475, EBI-350590;
CC       P45381; Q68J44: DUSP29; NbExp=3; IntAct=EBI-750475, EBI-1054321;
CC       P45381; Q14145: KEAP1; NbExp=4; IntAct=EBI-750475, EBI-751001;
CC       P45381; O75925: PIAS1; NbExp=3; IntAct=EBI-750475, EBI-629434;
CC       P45381; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-750475, EBI-947187;
CC       P45381; Q9H347: UBQLN3; NbExp=3; IntAct=EBI-750475, EBI-25832660;
CC       P45381; Q8IYU4: UBQLNL; NbExp=3; IntAct=EBI-750475, EBI-12295223;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Brain white matter, skeletal muscle, kidney,
CC       adrenal glands, lung and liver.
CC   -!- DISEASE: Canavan disease (CAND) [MIM:271900]: A rare neurodegenerative
CC       condition of infancy or childhood characterized by white matter
CC       vacuolization and demyelination that gives rise to a spongy appearance.
CC       The clinical features are onset in early infancy, atonia of neck
CC       muscles, hypotonia, hyperextension of legs and flexion of arms,
CC       blindness, severe mental defect, megalocephaly, and death by 18 months
CC       on the average. {ECO:0000269|PubMed:10407784,
CC       ECO:0000269|PubMed:10564886, ECO:0000269|PubMed:10909858,
CC       ECO:0000269|PubMed:12205125, ECO:0000269|PubMed:12638939,
CC       ECO:0000269|PubMed:12706335, ECO:0000269|PubMed:24036223,
CC       ECO:0000269|PubMed:28101991, ECO:0000269|PubMed:7599639,
CC       ECO:0000269|PubMed:7668285, ECO:0000269|PubMed:8023850,
CC       ECO:0000269|PubMed:8252036, ECO:0000269|PubMed:8659549,
CC       ECO:0000269|PubMed:9452117}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the AspA/AstE family. Aspartoacylase subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S67156; AAB29190.1; -; mRNA.
DR   EMBL; BC029128; AAH29128.1; -; mRNA.
DR   CCDS; CCDS11028.1; -.
DR   PIR; S38538; S38538.
DR   RefSeq; NP_000040.1; NM_000049.2.
DR   RefSeq; NP_001121557.1; NM_001128085.1.
DR   RefSeq; XP_016880150.1; XM_017024661.1.
DR   PDB; 2I3C; X-ray; 2.80 A; A/B=2-313.
DR   PDB; 2O4H; X-ray; 2.70 A; A/B=1-313.
DR   PDB; 2O53; X-ray; 2.70 A; A/B=1-313.
DR   PDB; 2Q51; X-ray; 2.80 A; A/B=2-313.
DR   PDB; 4MRI; X-ray; 2.80 A; A/B=1-313.
DR   PDB; 4MXU; X-ray; 2.60 A; A/B=1-313.
DR   PDB; 4NFR; X-ray; 3.00 A; A/B=1-313.
DR   PDB; 4TNU; X-ray; 2.90 A; A/B=1-313.
DR   PDBsum; 2I3C; -.
DR   PDBsum; 2O4H; -.
DR   PDBsum; 2O53; -.
DR   PDBsum; 2Q51; -.
DR   PDBsum; 4MRI; -.
DR   PDBsum; 4MXU; -.
DR   PDBsum; 4NFR; -.
DR   PDBsum; 4TNU; -.
DR   AlphaFoldDB; P45381; -.
DR   SMR; P45381; -.
DR   BioGRID; 106935; 11.
DR   DIP; DIP-60793N; -.
DR   IntAct; P45381; 12.
DR   STRING; 9606.ENSP00000263080; -.
DR   DrugBank; DB00128; Aspartic acid.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   DrugBank; DB14548; Zinc sulfate, unspecified form.
DR   DrugCentral; P45381; -.
DR   iPTMnet; P45381; -.
DR   PhosphoSitePlus; P45381; -.
DR   BioMuta; ASPA; -.
DR   MassIVE; P45381; -.
DR   PaxDb; P45381; -.
DR   PeptideAtlas; P45381; -.
DR   ProteomicsDB; 55676; -.
DR   Antibodypedia; 10844; 325 antibodies from 32 providers.
DR   DNASU; 443; -.
DR   Ensembl; ENST00000263080.3; ENSP00000263080.2; ENSG00000108381.11.
DR   Ensembl; ENST00000456349.6; ENSP00000409976.2; ENSG00000108381.11.
DR   GeneID; 443; -.
DR   KEGG; hsa:443; -.
DR   MANE-Select; ENST00000263080.3; ENSP00000263080.2; NM_000049.4; NP_000040.1.
DR   AGR; HGNC:756; -.
DR   CTD; 443; -.
DR   DisGeNET; 443; -.
DR   GeneCards; ASPA; -.
DR   GeneReviews; ASPA; -.
DR   HGNC; HGNC:756; ASPA.
DR   HPA; ENSG00000108381; Tissue enhanced (brain, kidney).
DR   MalaCards; ASPA; -.
DR   MIM; 271900; phenotype.
DR   MIM; 608034; gene.
DR   neXtProt; NX_P45381; -.
DR   OpenTargets; ENSG00000108381; -.
DR   Orphanet; 314918; Mild Canavan disease.
DR   Orphanet; 314911; Severe Canavan disease.
DR   PharmGKB; PA25055; -.
DR   VEuPathDB; HostDB:ENSG00000108381; -.
DR   eggNOG; ENOG502QRAK; Eukaryota.
DR   GeneTree; ENSGT00390000001189; -.
DR   HOGENOM; CLU_083292_0_0_1; -.
DR   InParanoid; P45381; -.
DR   OMA; THGNEIN; -.
DR   OrthoDB; 35794at2759; -.
DR   PhylomeDB; P45381; -.
DR   TreeFam; TF328708; -.
DR   BioCyc; MetaCyc:HS03094-MON; -.
DR   BRENDA; 3.5.1.15; 2681.
DR   PathwayCommons; P45381; -.
DR   Reactome; R-HSA-8963693; Aspartate and asparagine metabolism.
DR   SignaLink; P45381; -.
DR   SIGNOR; P45381; -.
DR   BioGRID-ORCS; 443; 5 hits in 1148 CRISPR screens.
DR   ChiTaRS; ASPA; human.
DR   EvolutionaryTrace; P45381; -.
DR   GenomeRNAi; 443; -.
DR   Pharos; P45381; Tbio.
DR   PRO; PR:P45381; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P45381; protein.
DR   Bgee; ENSG00000108381; Expressed in corpus callosum and 164 other tissues.
DR   ExpressionAtlas; P45381; baseline and differential.
DR   Genevisible; P45381; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0004046; F:aminoacylase activity; TAS:ProtInc.
DR   GO; GO:0019807; F:aspartoacylase activity; IEA:UniProtKB-EC.
DR   GO; GO:0016811; F:hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides; IBA:GO_Central.
DR   GO; GO:0016788; F:hydrolase activity, acting on ester bonds; IEA:InterPro.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006083; P:acetate metabolic process; IEA:Ensembl.
DR   GO; GO:0006533; P:aspartate catabolic process; TAS:ProtInc.
DR   GO; GO:0022010; P:central nervous system myelination; IEA:Ensembl.
DR   GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IEA:Ensembl.
DR   CDD; cd06909; M14_ASPA; 1.
DR   Gene3D; 2.20.25.160; -; 1.
DR   Gene3D; 3.40.630.10; Zn peptidases; 1.
DR   HAMAP; MF_00704; Aspartoacylase; 1.
DR   InterPro; IPR016708; Aspartoacylase.
DR   InterPro; IPR007036; Aste_AspA.
DR   PANTHER; PTHR15162; ASPARTOACYLASE; 1.
DR   PANTHER; PTHR15162:SF9; ASPARTOACYLASE; 1.
DR   Pfam; PF04952; AstE_AspA; 1.
DR   PIRSF; PIRSF018001; Aspartoacylase; 1.
DR   SUPFAM; SSF53187; Zn-dependent exopeptidases; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cytoplasm; Disease variant; Hydrolase; Leukodystrophy;
KW   Metal-binding; Nucleus; Reference proteome; Zinc.
FT   CHAIN           1..313
FT                   /note="Aspartoacylase"
FT                   /id="PRO_0000216871"
FT   ACT_SITE        178
FT                   /evidence="ECO:0000269|PubMed:17027983"
FT   BINDING         21
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT   BINDING         24
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT   BINDING         63
FT                   /ligand="substrate"
FT   BINDING         70..71
FT                   /ligand="substrate"
FT   BINDING         116
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT   BINDING         164..168
FT                   /ligand="substrate"
FT   BINDING         178
FT                   /ligand="substrate"
FT   BINDING         288
FT                   /ligand="substrate"
FT   VARIANT         16
FT                   /note="I -> T (in CAND; <0.5% residual enzyme activity;
FT                   dbSNP:rs769653717)"
FT                   /evidence="ECO:0000269|PubMed:10407784,
FT                   ECO:0000269|PubMed:8659549"
FT                   /id="VAR_039079"
FT   VARIANT         21
FT                   /note="H -> P (in CAND)"
FT                   /evidence="ECO:0000269|PubMed:10909858"
FT                   /id="VAR_016778"
FT   VARIANT         24
FT                   /note="E -> G (in CAND; dbSNP:rs104894551)"
FT                   /evidence="ECO:0000269|PubMed:12638939"
FT                   /id="VAR_016782"
FT   VARIANT         24
FT                   /note="E -> K (in CAND; <1% residual enzyme activity)"
FT                   /evidence="ECO:0000269|PubMed:28101991"
FT                   /id="VAR_078086"
FT   VARIANT         27
FT                   /note="G -> R (in CAND; 3% residual enzyme activity;
FT                   dbSNP:rs766328537)"
FT                   /evidence="ECO:0000269|PubMed:10407784,
FT                   ECO:0000269|PubMed:8659549"
FT                   /id="VAR_039080"
FT   VARIANT         30
FT                   /note="L -> P (in CAND; <1% residual enzyme activity;
FT                   dbSNP:rs1555538144)"
FT                   /evidence="ECO:0000269|PubMed:28101991"
FT                   /id="VAR_078087"
FT   VARIANT         57
FT                   /note="A -> T (in CAND)"
FT                   /evidence="ECO:0000269|PubMed:10909858"
FT                   /id="VAR_016779"
FT   VARIANT         57
FT                   /note="A -> V (in CAND; <1% residual enzyme activity;
FT                   dbSNP:rs1555538148)"
FT                   /evidence="ECO:0000269|PubMed:28101991"
FT                   /id="VAR_078088"
FT   VARIANT         63
FT                   /note="R -> T (in CAND; <1% residual enzyme activity;
FT                   dbSNP:rs1555538151)"
FT                   /evidence="ECO:0000269|PubMed:28101991"
FT                   /id="VAR_078089"
FT   VARIANT         68
FT                   /note="D -> A (in CAND)"
FT                   /evidence="ECO:0000269|PubMed:12638939"
FT                   /id="VAR_016783"
FT   VARIANT         69
FT                   /note="L -> R (in CAND; <1% residual enzyme activity;
FT                   dbSNP:rs776777887)"
FT                   /evidence="ECO:0000269|PubMed:28101991"
FT                   /id="VAR_078090"
FT   VARIANT         101
FT                   /note="G -> V (in CAND; <1% residual enzyme activity)"
FT                   /evidence="ECO:0000269|PubMed:28101991"
FT                   /id="VAR_078091"
FT   VARIANT         114
FT                   /note="D -> E (in CAND; <0.5% residual enzyme activity)"
FT                   /evidence="ECO:0000269|PubMed:8659549"
FT                   /id="VAR_039081"
FT   VARIANT         114
FT                   /note="D -> Y (in CAND; dbSNP:rs1446467099)"
FT                   /evidence="ECO:0000269|PubMed:12205125"
FT                   /id="VAR_016784"
FT   VARIANT         123
FT                   /note="G -> E (in CAND; about 25% residual enzyme activity;
FT                   dbSNP:rs1057521115)"
FT                   /evidence="ECO:0000269|PubMed:8659549"
FT                   /id="VAR_039082"
FT   VARIANT         129
FT                   /note="E -> K (in CAND; <1% residual enzyme activity;
FT                   dbSNP:rs773049803)"
FT                   /evidence="ECO:0000269|PubMed:28101991"
FT                   /id="VAR_078092"
FT   VARIANT         143
FT                   /note="I -> T (in CAND; dbSNP:rs777936704)"
FT                   /evidence="ECO:0000269|PubMed:9452117"
FT                   /id="VAR_004995"
FT   VARIANT         152
FT                   /note="C -> R (in CAND; loss of activity;
FT                   dbSNP:rs104894548)"
FT                   /evidence="ECO:0000269|PubMed:7599639"
FT                   /id="VAR_004996"
FT   VARIANT         152
FT                   /note="C -> W (in CAND)"
FT                   /evidence="ECO:0000269|PubMed:12638939"
FT                   /id="VAR_016785"
FT   VARIANT         152
FT                   /note="C -> Y (in CAND; <0.5% residual enzyme activity)"
FT                   /evidence="ECO:0000269|PubMed:8659549"
FT                   /id="VAR_039083"
FT   VARIANT         168
FT                   /note="R -> C (in CAND; undetectable enzyme activity;
FT                   dbSNP:rs937670540)"
FT                   /evidence="ECO:0000269|PubMed:8659549"
FT                   /id="VAR_039084"
FT   VARIANT         168
FT                   /note="R -> H (in CAND; dbSNP:rs770706390)"
FT                   /evidence="ECO:0000269|PubMed:10909858"
FT                   /id="VAR_016780"
FT   VARIANT         170
FT                   /note="I -> T (in CAND; 5.5% residual enzyme activity;
FT                   dbSNP:rs144321760)"
FT                   /evidence="ECO:0000269|PubMed:28101991"
FT                   /id="VAR_078093"
FT   VARIANT         176..177
FT                   /note="Missing (in CAND)"
FT                   /evidence="ECO:0000269|PubMed:7668285"
FT                   /id="VAR_004997"
FT   VARIANT         177
FT                   /note="I -> T (in CAND; Loss of catalytic activity)"
FT                   /evidence="ECO:0000269|PubMed:24036223"
FT                   /id="VAR_078094"
FT   VARIANT         180
FT                   /note="G -> V (in CAND; <1% residual enzyme activity;
FT                   dbSNP:rs1014551540)"
FT                   /evidence="ECO:0000269|PubMed:28101991"
FT                   /id="VAR_078095"
FT   VARIANT         181
FT                   /note="P -> T (in CAND; dbSNP:rs786204572)"
FT                   /evidence="ECO:0000269|PubMed:10909858"
FT                   /id="VAR_016781"
FT   VARIANT         183
FT                   /note="P -> H (in CAND; dbSNP:rs1555539857)"
FT                   /evidence="ECO:0000269|PubMed:10407784"
FT                   /id="VAR_039085"
FT   VARIANT         186
FT                   /note="V -> F (in CAND)"
FT                   /evidence="ECO:0000269|PubMed:10407784"
FT                   /id="VAR_039086"
FT   VARIANT         195
FT                   /note="M -> R (in CAND)"
FT                   /evidence="ECO:0000269|PubMed:10407784"
FT                   /id="VAR_039087"
FT   VARIANT         204
FT                   /note="D -> H (in CAND; 12% residual enzyme activity)"
FT                   /evidence="ECO:0000269|PubMed:28101991"
FT                   /id="VAR_078096"
FT   VARIANT         231
FT                   /note="Y -> C (in CAND; dbSNP:rs104894550)"
FT                   /evidence="ECO:0000269|PubMed:10564886"
FT                   /id="VAR_016786"
FT   VARIANT         244
FT                   /note="H -> R (in CAND; dbSNP:rs1057516995)"
FT                   /evidence="ECO:0000269|PubMed:12638939"
FT                   /id="VAR_016787"
FT   VARIANT         248
FT                   /note="Q -> R (in CAND; <1% residual enzyme activity)"
FT                   /evidence="ECO:0000269|PubMed:28101991"
FT                   /id="VAR_078097"
FT   VARIANT         249
FT                   /note="D -> V (in CAND; dbSNP:rs104894552)"
FT                   /evidence="ECO:0000269|PubMed:12205125,
FT                   ECO:0000269|PubMed:12638939"
FT                   /id="VAR_016788"
FT   VARIANT         274
FT                   /note="G -> R (in CAND; dbSNP:rs761064915)"
FT                   /evidence="ECO:0000269|PubMed:10407784,
FT                   ECO:0000269|PubMed:7668285"
FT                   /id="VAR_004998"
FT   VARIANT         280
FT                   /note="P -> L (in CAND; dbSNP:rs1555541310)"
FT                   /evidence="ECO:0000269|PubMed:10407784"
FT                   /id="VAR_039088"
FT   VARIANT         280
FT                   /note="P -> S (in CAND; dbSNP:rs750505963)"
FT                   /evidence="ECO:0000269|PubMed:10407784"
FT                   /id="VAR_039089"
FT   VARIANT         285
FT                   /note="E -> A (in CAND; predominant mutation in Ashkenazi
FT                   Jewish population; 99% loss of activity; dbSNP:rs28940279)"
FT                   /evidence="ECO:0000269|PubMed:12706335,
FT                   ECO:0000269|PubMed:28101991, ECO:0000269|PubMed:8023850,
FT                   ECO:0000269|PubMed:8252036, ECO:0000269|PubMed:8659549"
FT                   /id="VAR_004999"
FT   VARIANT         286
FT                   /note="A -> D (in CAND; <1% residual enzyme activity;
FT                   dbSNP:rs1414684396)"
FT                   /evidence="ECO:0000269|PubMed:28101991"
FT                   /id="VAR_078098"
FT   VARIANT         287
FT                   /note="A -> T (in CAND; dbSNP:rs774323189)"
FT                   /evidence="ECO:0000269|PubMed:10407784"
FT                   /id="VAR_039090"
FT   VARIANT         295
FT                   /note="F -> S (in CAND)"
FT                   /evidence="ECO:0000269|PubMed:10407784,
FT                   ECO:0000269|PubMed:7668285"
FT                   /id="VAR_005000"
FT   VARIANT         305
FT                   /note="A -> E (in CAND; pan-European origin; most prevalent
FT                   among non-Jewish CAND patients; probably the most ancient
FT                   mutation; loss of activity; dbSNP:rs28940574)"
FT                   /evidence="ECO:0000269|PubMed:10407784,
FT                   ECO:0000269|PubMed:7668285, ECO:0000269|PubMed:8023850,
FT                   ECO:0000269|PubMed:8659549"
FT                   /id="VAR_005001"
FT   VARIANT         310
FT                   /note="C -> G (in dbSNP:rs376854191)"
FT                   /evidence="ECO:0000269|PubMed:8659549"
FT                   /id="VAR_039091"
FT   MUTAGEN         71
FT                   /note="R->K: Reduces activity by 99%."
FT                   /evidence="ECO:0000269|PubMed:18293939"
FT   MUTAGEN         164
FT                   /note="Y->F: Reduces activity by 99%."
FT                   /evidence="ECO:0000269|PubMed:18293939"
FT   MUTAGEN         168
FT                   /note="R->K: Reduces activity by 99%."
FT                   /evidence="ECO:0000269|PubMed:18293939"
FT   MUTAGEN         178
FT                   /note="E->A: Reduces activity by 99%."
FT                   /evidence="ECO:0000269|PubMed:17027983,
FT                   ECO:0000269|PubMed:18293939"
FT   MUTAGEN         178
FT                   /note="E->D: Abolishes enzymatic activity."
FT                   /evidence="ECO:0000269|PubMed:17027983,
FT                   ECO:0000269|PubMed:18293939"
FT   MUTAGEN         178
FT                   /note="E->Q: Abolishes enzymatic activity."
FT                   /evidence="ECO:0000269|PubMed:17027983,
FT                   ECO:0000269|PubMed:18293939"
FT   MUTAGEN         285
FT                   /note="E->D: 5-fold decrease in activity."
FT                   /evidence="ECO:0000269|PubMed:12706335"
FT   MUTAGEN         288
FT                   /note="Y->F: Reduces activity by 99%."
FT                   /evidence="ECO:0000269|PubMed:18293939"
FT   STRAND          14..18
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   HELIX           25..34
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   HELIX           39..41
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          48..53
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   HELIX           55..59
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          65..67
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   HELIX           69..71
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   HELIX           75..78
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          84..86
FT                   /evidence="ECO:0007829|PDB:4TNU"
FT   HELIX           88..100
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          105..108
FT                   /evidence="ECO:0007829|PDB:2O4H"
FT   STRAND          110..117
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          119..121
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          123..129
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   HELIX           134..147
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          152..156
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          160..162
FT                   /evidence="ECO:0007829|PDB:2O4H"
FT   HELIX           167..170
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          171..181
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   HELIX           189..210
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          218..229
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          237..239
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          241..243
FT                   /evidence="ECO:0007829|PDB:2O53"
FT   TURN            245..249
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          259..263
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          269..271
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          274..276
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          278..282
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   HELIX           286..288
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   TURN            289..292
FT                   /evidence="ECO:0007829|PDB:4MXU"
FT   STRAND          294..305
FT                   /evidence="ECO:0007829|PDB:4MXU"
SQ   SEQUENCE   313 AA;  35735 MW;  33C0B9B07839E7F5 CRC64;
     MTSCHIAEEH IQKVAIFGGT HGNELTGVFL VKHWLENGAE IQRTGLEVKP FITNPRAVKK
     CTRYIDCDLN RIFDLENLGK KMSEDLPYEV RRAQEINHLF GPKDSEDSYD IIFDLHNTTS
     NMGCTLILED SRNNFLIQMF HYIKTSLAPL PCYVYLIEHP SLKYATTRSI AKYPVGIEVG
     PQPQGVLRAD ILDQMRKMIK HALDFIHHFN EGKEFPPCAI EVYKIIEKVD YPRDENGEIA
     AIIHPNLQDQ DWKPLHPGDP MFLTLDGKTI PLGGDCTVYP VFVNEAAYYE KKEAFAKTTK
     LTLNAKSIRC CLH
//
